Search
forLearn
5 / 801 resultsResearch
5 / 1000+ results
research Effects of a new mild shampoo for preventing hair loss in Asian by a simple hand-held phototrichogram technique
The new mild shampoo helped prevent hair loss in the subjects.
research Gray Hair: From Preventive to Treatment
Gray hair can potentially be managed or reversed with treatments that boost melanin production and address nutritional deficiencies.
research The Efficacy and Safety of AP-FHG0604T on Female Pattern Hair Loss: A Randomized Double-blind Placebo-controlled Clinical Trial
research Finasteride 98319‐26‐7
research Efficacy and tolerability of HDMHG0401-10 in Patients with Androgenetic Alopecia: A Randomized Double-blind Placebo-controlled Trial
HDMHG0401-10 treatment significantly improved hair count and was better than a placebo in reducing hair loss in men with hereditary hair loss, with no major side effects.
Community Join
5 / 1000+ resultscommunity AH-001 another topical AR degrader beside GT20029, completed Phase I
AH-001 is a new topical treatment designed to degrade androgen receptors, targeting the root cause of androgenetic alopecia without the side effects of oral treatments like finasteride. It has shown a strong safety profile and good local tolerability in early trials.
community HMI 115 hasn't done phase one yet for AGA?
User asks if HMI 115 hasn't done phase 1 for AGA in humans. Conversation includes treatments Min, Fin, and RU.
community mallia therapeutics 8T3 scd83 molecule for ffa/lpp mainly and aga
A user applied the 8T3 product for hair loss, targeting LPP and AGA, and plans to update on its effectiveness. The product uses a saline buffered phosphate vehicle, suitable for those intolerant to ethanolic vehicles.
community What's going on with hmi115? The Phase 2 was concluded Nov2024 but no news
Hmi115, a prolactin receptor blocker, showed promise for hair growth, but results from Phase 2 trials have not been published. ABS-201, an AI-based analog, is expected to begin trials in December 2025, while commercialization of treatments like PP-405 is anticipated around 2027.
community A warning to anyone considering 3rd party sourcing PP405 or its analogs
Be cautious when sourcing PP405 or its analogs from third-party suppliers due to potential safety risks and lack of regulatory approval. The conversation highlights concerns about counterfeit products and the absence of reliable testing, making it risky to use such treatments.